Odevixibat reduces markers of progressive familial intrahepatic cholestasis in children

odevixibat reduces markers of progressive familial intrahepatic cholestasis in children

Sumary of Odevixibat reduces markers of progressive familial intrahepatic cholestasis in children:

  • November 15, 2021 1 min read Source/Disclosures Published by: Source: Gonzales E.
  • Disclosures: Gonzales reports receiving study funding from Albireo Pharma Inc. and consulting for Albireo, Laboratoires CTRS and Mirum Pharma.
  • “Progressive familial intrahepatic cholestasis, or PFIC, is a group of rare genetic liver diseases characterized by chronic cholestasis, high serum bile acids and severe pruritis being the hallmarks of the disease and progressive liver disease.
  • Lysophosphatidic acid mainly produced by autotaxin and serum bile acids are both possible pruritic mediators,” Emmanuel Gonzales, MD, PhD, of the Hôpital Bicêtre at the Universite Paris-Sud, said during his presentation at The Liver Meeting Digital Experience.
  • ” Aimed to explore the relationship between odevixibat, an ileal bile acid transporter inhibitor, and PFIC parameters, researchers used pooled study data from phase 3 PEDFIC 1 and PEDFIC 2 studies.
  • PEDFIC 2 is the ongoing, 72week extension study among patients of any age with PFIC dosed with odevixibat 120 g/kg daily.
  • Significant correlations were observed between reductions in each pair of these three parameters,” Gonzales concluded.

Want to know more click here go to source.

From -

Close

Site Language


Popular Posts

1,862

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close